Nearing 25 million cases of COVID, over 800,000 deaths, and economic devastation on a global scale, the world scientific community will come together for a series of virtual meetings starting on June 16th. This monthly series will bring together expert scientists on the forefront of COVID research into viral origins & variation, virus biology, host response, and antivirals & vaccines. It is designed to stimulate ideas and collaborations among scientists with the goal of hastening a solution to vanquish this worldwide disease.
COVID-R3-#1 |
Invited Talks only |
June 16 - 17, 2020 |
COVID-R3 #2 |
Invited Talks only |
July 21 - 22, 2020 |
COVID-R3 #3 |
Invited & Selected Talks/Posters |
August 25 - 26, 2020 |
Sessions & Confirmed Speakers (COVID-R3-#3) Times posted in US Eastern Daily Time
Session I: Host-virus Interactions/Structure
Tuesday, August 25: 9:30am EDT
Co-Chairs: Paul McCray, University of Iowa & Anthony Fehr, University of Kansas
Avantika Lal, NVIDIA Corporation - Genome-wide Bioinformatic Analyses Predict Key Host and Viral Factors in SARS-CoV-2 Pathogenesis
Wenlin Ren, Tsinghua University - Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2
Wim van der Poel, Wageningen University & Research - SARS-CoV2 Outbreaks in Farmed Mink, Netherlands April-August 2020
Jianxun Qi, Chinese Academy of Sciences, Beijing - Structural Insights of Virus Entry and Blocking by MABs and Inhibitors
Hong Liu, Chinese Academy of Sciences, Shanghai - Structure-based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease
Yogesh Gupta, University of Texas San Antonio - Structural Basis of RNA Cap Modification by SARS-CoV-2 Coronavirus
Karla Satchell, Northwestern University - High Resolution Structures of the SARS-CoV-2 nsp16/nsp10 2’-O-methyltransferase Reveals Strategies for Structure-based Inhibitor Design
Session II: Coronavirus Biology
Tuesday, August 25: 2:00 pm EDT
Co-Chairs: Carolyn Machamer, Johns Hopkins Medical Institute & Susan Weiss, University of Pennsylvania Perelman School of Medicine
Cynthia M. Otto, University of Pennsylvania - The Scent of COVID-19: How Dogs May Help in Rapid Screening
Silvia Rouskin, Whitehead Institute, MIT - Structure of the Full SARS-CoV-2 RNA Genome in Infected Cells
Yousef Alhammad, University of Kansas - The SARS-CoV-2 Conserved Macrodomain is a Mono-ADP-ribosylhydrolase
Peter Kasson, University of Virginia - Unraveling Binding, Proteolytic Activation, and Entry of SARS-CoV-2 with Single-virus Microscopy
Miguel Ortiz Bezara, University of Iowa - Heterogeneous Expression of the SARS-Coronavirus-2 Receptor ACE2 in the Human Respiratory Tract
Eric Snijder, Leiden University Medical Center - The Coronavirus Escape Room
Yize Li, University of Pennsylvania - Activation of Double-stranded RNA Induced Innate Immune Responses During SARS-CoV-2 Infection
Session III: Pathogenesis & The Immune Response
Wednesday, August 26: 9:30am EDT
Co-Chairs: Mikala Egeblad, Cold Spring Harbor Laboratory & Adrian Hayday, King's College London
Jen-Laurent Casanova, The Rockefeller University - Inborn Errors of Immunity to SARS-CoV-2
Xin Zheng, Tongji Medical College, Huazhong University of Science & Technology - SARS-CoV-2 Infection Induces Sustained Humoral Immune Responses in Convalescent Patients Following Symptomatic COVID-19
Jacob Files, University of Alabama, Birmingham -Sustained Cellular Immune Dysregulation in Non-hospitalized Individuals Recovering from SARS-CoV-2 Infection
Yin Wu, King's College London - Age-related Antigen-receptor Dynamics of αβ and γδ T cells in SARS-CoV-2 Infection
Susan Baker, Loyola University of Chicago - Coronavirus EndoU/nsp15 Targets Viral Sequences to Evade Activating Host Sensors
Lok-Yin Roy Wong, University of Iowa - K18-hACE2 Mice for Studies of COVID-19 Treatments and Pathogenesis Including Anosmia
Michael Buchmeier, University of California, Irvine - A Coronavirus Model for Virally induced Autoimmune Disease in Mice
Adrienne Randolph, Harvard University - Multisystem Inflammatory Syndrome in Children (MIS-C)
Session IV: Roundtable/Vaccines/Antivirals Wednesday, August 26: 2:00pm EDT
Co-Chairs: Stanley Perlman, University of Iowa & Kizzmekia Corbett, National Institutes of Health
Roundtable Discussion: Role of Convalescent Plasma Therapy in COVID-19: Pros & Cons
Chair: Stanley Perlman, University of Iowa
Arturo Casadevall, John Hopkins School of Medicine - Deployment of Convalescent Plasma Against COVID-19
Paul Bieniasz, The Rockefeller University - Neutralizing Antibodies in Convalescent Plasma
Adrian Hayday, Kings College London - Discussant
Stanley Perlman, University of Iowa - Discussant
Vaccines/Antivirals
Chair: Kizzmekia Corbett, National Institutes of Health
Trevor Smith, Inovio Pharmaceuticals - Durability of Antibody and T Cell Immune Responses Induced by a SARS-CoV-2 DNA Vaccine in Rhesus Macaques Animal Challenge Study
Peter Palese, Icahn School of Medicine at Mount Sinai - Newcastle Disease Virus (NDV) Expressing the Spike Protein of SARS-CoV-2 as Vaccine Candidate
David Dulin, FAU Erlangen-Nuremberg - Targeting the SARS-CoV-2 Replicase for Antiviral Therapy: A Single-molecule Perspective
Tobias Janowitz, Cold Spring Harbor Laboratory - Famotidine Mechanism of Action and Use in Combination with Quantitative Host Symptom Tracking for COVID-19 in Non-hospitalized Patients
Virtual 2 day live meeting + archive access
~28 talks / 4 sessions
(late am/early pm)
~12 total hours with interactive Q&A |
|
Virtual posters with dedicated slack channels for each poster |
|
Leading Strand video archive access to talks |
Twitter for meeting news & general comments |
Pricing:
Virtual COVID-R3 #3 Package: $100
(Registrants may register for possible future COVID-R3 conferences for $85/conference)
Virtual Attendance packages include access to online Zoom-based oral sessions with live Q&A and access to the video archive on the Leading Strand for ~twelve weeks following each meeting. For registration questions please reach
Alicia Franco .